Jean-Paul Kress

Jean-Paul Kress

President, Chief Executive Officer and ChairmanatVor Biopharma· In the 2025 proxy

Pay in FY2025Vor Biopharma stock -41.1% the same year

Jean-Paul Kress was paid $65.0M in FY2025 (Dec). Vor Biopharma stock fell 41.1% that year.

Pay$100 in the stock at the end of FY24 → $59
Pay is from the Summary Compensation Table of each Vor Biopharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Vor BiopharmaPublic company · 1 yr
    • President, Chief Executive Officer and Chairman2025 – Present · 1 yrStock in role +18%
  2. Sanofi S.A.Public company
    • Director? – PresentNo stock prices for these years
  3. ErytechPublic company · 4 yr
    • Director2019 – 2023 · 4 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?